With Access Restricted, Aduhelm Appears Poised For A Slow Start
Payers Speak Out At ICER Public Meeting
Executive Summary
Reimbursement, health policy and medical experts predicted a slow rollout ahead for Biogen's new Alzheimer's treatment at a public meeting sponsored by ICER.
You may also be interested in...
Biogen Says Physician Debate About Aduhelm More ‘Pervasive’ Than Anticipated
CEO Michel Vounatsos and US president Alisha Alaimo outlined plans to overcome the Alzheimer’s drug’s launch challenges and hinted at lower sales expectations at a Morgan Stanley investor event.
Podcast: What's Ahead For Aduhelm's Launch And Reimbursement
Pink Sheet and Scrip editors join Datamonitor Healthcare analysts to discuss Biogen's Aduhelm for Alzheimer's disease, including the expected launch trajectory, early commercial barriers to uptake and the Medicare reimbursement environment.
Podcast: What's Ahead For Aduhelm's Launch And Reimbursement
Scrip and Pink Sheet editors join Datamonitor Healthcare analysts to discuss Biogen's Aduhelm for Alzheimer's disease, including the expected launch trajectory, early commercial barriers to uptake and the Medicare reimbursement environment.